Testing transplant timing guided by leftover leukemia cells in acute myeloid leukemia
Compares transplant decisions guided by leftover leukemia cells in adults with high-risk acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: MRD Response-adapted Allo-HSCT for Adverse-risk AML
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 16 to 65 with newly diagnosed acute myeloid leukemia (AML) in the adverse-risk group who reached complete remission after 1 or 2 rounds of induction chemotherapy.
- Age
- 16 to 65 years at diagnosis
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed AML, adverse-risk group by ELN 2022 criteria, in complete remission (CR) after 1 or 2 courses of induction chemotherapy
- Earlier treatment
- Must have reached CR after 1 or 2 courses of induction chemotherapy
Main reasons for not taking part
- AML in the favorable- or intermediate-risk group by ELN 2022 criteria
- CR reached only after 3 or more courses of induction chemotherapy, or no CR
- ECOG PS score of 2 or more
- Other illnesses or mental diseases that affect safety, consent, follow-up or result interpretation
- Younger than 16 or older than 65 years at diagnosis
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 65 years old?
Source: NCT06301425, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Xiaodong MoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT06301425
- Record updated
- 10 July 2024
- Original description
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.Read full original descriptionShow less
Measurable Residual Disease Response-adapted Allogeneic Hematopoietic Stem Cell Transplantation for Adverse-risk Acute Myeloid Leukemia: an Open-label, Randomized, Controlled Trial（TROPHY-AML01）
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
Inclusion: Newly diagnosed AML; Categorized into adverse-risk group according to ELN 2022 criteria; 16-65 years of age at the time of diagnosis; achieving CR after 1 or 2 courses of induction chemotherapies; ECOG PS score of 0 to 1 5) It needs consent from the patients or/and legal guardian, and signature on the Informed Consent.
Exclusion: Patients with other comorbidities or mental diseases that influence the life safety and compliance of patients as well as affect informed consent, enrollment in the research, follow-up visit or result interpretation; < 16 years, or older than 65 years at the time of diagnosis; Newly diagnosed AML, but categorized into favorite- or intermediate-risk group according to ELN 2022 criteria; Achieving CR after 3 or more courses of induction chemotherapies, or could not achieve CR after induction chemotherapies; ECOG PS score of 2 or more.